Entrada Therapeutics, Inc.
TRDA
$7.46
$0.010.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -53.95% | -95.74% | -96.53% | -91.75% | -97.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -53.95% | -95.74% | -96.53% | -91.75% | -97.94% |
| Cost of Revenue | -6.62% | 3.06% | -3.44% | 22.73% | 18.24% |
| Gross Profit | 4.05% | -179.43% | -875.50% | -214.43% | -157.34% |
| SG&A Expenses | -3.94% | -1.46% | -5.16% | 3.34% | 18.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.02% | 1.96% | -3.83% | 18.04% | 18.24% |
| Operating Income | 4.03% | -94.14% | -587.03% | -117.25% | -187.69% |
| Income Before Tax | 0.46% | -128.71% | -5,187.14% | -173.60% | -174.28% |
| Income Tax Expenses | -80.34% | -- | 104.92% | 135.16% | -93.55% |
| Earnings from Continuing Operations | 0.79% | -128.93% | -3,562.78% | -214.52% | -178.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.79% | -128.93% | -3,562.78% | -214.52% | -178.32% |
| EBIT | 4.03% | -94.14% | -587.03% | -117.25% | -187.69% |
| EBITDA | 3.70% | -99.09% | -708.66% | -121.13% | -184.32% |
| EPS Basic | 2.87% | -124.74% | -3,498.56% | -208.16% | -164.76% |
| Normalized Basic EPS | 2.54% | -124.55% | -4,841.59% | -168.06% | -161.42% |
| EPS Diluted | 2.87% | -124.74% | -4,692.20% | -204.11% | -167.27% |
| Normalized Diluted EPS | 2.54% | -124.55% | -5,118.69% | -168.06% | -163.80% |
| Average Basic Shares Outstanding | 2.14% | 1.86% | 1.86% | 2.05% | 20.94% |
| Average Diluted Shares Outstanding | 2.14% | 1.86% | -3.36% | 2.05% | 16.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |